Sean Lal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sean Lal has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Lisa Nguyen
5 shared publicationsCristobal dos Remedios
Department of Anatomy and Histology, Bosch Institute, Sydney Medical School, The University of Sydney, Sydney, Australia
4 shared publications- Amy Li
School of Medical Sciences, The University of Sydney, Sydney, NSW, Australia.
3 shared publications - Cristobal G. dos Remedios
Victor Chang Cardiac Research Institute, Darlinghurst, NSW, Australia (C.G.d.R.).
2 shared publications Gareth Denyer
2 shared publicationsPeter Macdonald
Heart-Lung Transplant Unit, St. Vincent's Hospital, Sydney, Australia
2 shared publications
Latest Publications
- 3 May 2018
- Published by BMJ in Heart Asia
- Vol. 10 (1) , e010999
Renin–angiotensin–aldosterone inhibition improves right ventricular function: a meta-analysis
The benefits of inhibiting the renin–angiotensin–aldosterone system (RAAS) are well established for left ventricular dysfunction, but remain unknown for right ventricular (RV) dysfunction. The aim of the current meta-analysis is to investigate the role of RAAS inhibition on RV function in those with or at risk of RV dysfunction. Medline, PubMed, EMBASE and Cochrane Libraries were systematically searched and 12 studies were included for statistical synthesis, comprising 265 RAAS inhibition treatment patients and 265 placebo control patients. The treatment arm showed a trend towards increased RV ejection fraction (weighted mean difference (WMD)=0.95, 95% CI −0.12 to 2.02, p=0.08) compared with the control arm. Subgroup analysis demonstrated a trend towards improvement in RV ejection fraction in patients receiving angiotensin receptor blockers compared with control (WMD=1.11, 95% CI −0.02 to 2.26, p=0.06), but not in the respective comparison for ACE inhibitors (WMD=0.07, 95% CI −2.74 to 2.87, p>0.05). No differences were shown between the two groups with regard to maximal oxygen consumption, RV end-systolic volume, RV end-diastolic volume, duration of cardiopulmonary exercise testing, and resting and maximal heart rate. Mild adverse drug reactions were common but evenly distributed between the treatment and control groups. The current meta-analysis highlights that there may be a role for RAAS inhibition, particularly treatment with angiotensin receptor blockers, in those with or at risk of RV dysfunction. However, further confirmation will be required by larger prospective trials.
- 3 May 2018
- Published by BMJ in Heart Asia
- Vol. 10 (1) , e010999
Renin–angiotensin–aldosterone inhibition improves right ventricular function: a meta-analysis
The benefits of inhibiting the renin–angiotensin–aldosterone system (RAAS) are well established for left ventricular dysfunction, but remain unknown for right ventricular (RV) dysfunction. The aim of the current meta-analysis is to investigate the role of RAAS inhibition on RV function in those with or at risk of RV dysfunction. Medline, PubMed, EMBASE and Cochrane Libraries were systematically searched and 12 studies were included for statistical synthesis, comprising 265 RAAS inhibition treatment patients and 265 placebo control patients. The treatment arm showed a trend towards increased RV ejection fraction (weighted mean difference (WMD)=0.95, 95% CI −0.12 to 2.02, p=0.08) compared with the control arm. Subgroup analysis demonstrated a trend towards improvement in RV ejection fraction in patients receiving angiotensin receptor blockers compared with control (WMD=1.11, 95% CI −0.02 to 2.26, p=0.06), but not in the respective comparison for ACE inhibitors (WMD=0.07, 95% CI −2.74 to 2.87, p>0.05). No differences were shown between the two groups with regard to maximal oxygen consumption, RV end-systolic volume, RV end-diastolic volume, duration of cardiopulmonary exercise testing, and resting and maximal heart rate. Mild adverse drug reactions were common but evenly distributed between the treatment and control groups. The current meta-analysis highlights that there may be a role for RAAS inhibition, particularly treatment with angiotensin receptor blockers, in those with or at risk of RV dysfunction. However, further confirmation will be required by larger prospective trials.
- 1 February 2017
- Published by Elsevier in Biophysical Journal
- Vol. 112 (3) , 557a
Increased Phosphorylation of Cardiac Myosin Binding Protein C and Increased Expression of Troponin I in Normal Human Ageing
- 1 February 2017
- Published by Elsevier in Biophysical Journal
- Vol. 112 (3) , 557a
Increased Phosphorylation of Cardiac Myosin Binding Protein C and Increased Expression of Troponin I in Normal Human Ageing
- 1 July 2016
- Published by Wiley in Proteomics
- Vol. 16 (17) , 2319-2326
Tissue microarray profiling in human heart failure
Tissue MicroArrays (TMAs) are a versatile tool for high‐throughput protein screening, allowing qualitative analysis of a large number of samples on a single slide. We have developed a customizable TMA system that uniquely utilizes cryopreserved human cardiac samples from both heart failure and donor patients to produce formalin‐fixed paraffin‐embedded sections. Confirmatory upstream or downstream molecular studies can then be performed on the same (biobanked) cryopreserved tissue. In a pilot study, we applied our TMAs to screen for the expression of four‐and‐a‐half LIM‐domain 2 (FHL2), a member of the four‐and‐a‐half LIM family. This protein has been implicated in the pathogenesis of heart failure in a variety of animal models. While FHL2 is abundant in the heart, not much is known about its expression in human heart failure. For this purpose, we generated an affinity‐purified rabbit polyclonal anti‐human FHL2 antibody. Our TMAs allowed high‐throughput profiling of FHL2 protein using qualitative and semiquantitative immunohistochemistry that proved complementary to Western blot analysis. We demonstrated a significant relative reduction in FHL2 protein expression across different forms of human heart failure.
- 1 July 2016
- Published by Wiley in Proteomics
- Vol. 16 (17) , 2319-2326
Tissue microarray profiling in human heart failure
Tissue MicroArrays (TMAs) are a versatile tool for high‐throughput protein screening, allowing qualitative analysis of a large number of samples on a single slide. We have developed a customizable TMA system that uniquely utilizes cryopreserved human cardiac samples from both heart failure and donor patients to produce formalin‐fixed paraffin‐embedded sections. Confirmatory upstream or downstream molecular studies can then be performed on the same (biobanked) cryopreserved tissue. In a pilot study, we applied our TMAs to screen for the expression of four‐and‐a‐half LIM‐domain 2 (FHL2), a member of the four‐and‐a‐half LIM family. This protein has been implicated in the pathogenesis of heart failure in a variety of animal models. While FHL2 is abundant in the heart, not much is known about its expression in human heart failure. For this purpose, we generated an affinity‐purified rabbit polyclonal anti‐human FHL2 antibody. Our TMAs allowed high‐throughput profiling of FHL2 protein using qualitative and semiquantitative immunohistochemistry that proved complementary to Western blot analysis. We demonstrated a significant relative reduction in FHL2 protein expression across different forms of human heart failure.
- 15 January 2016
- Published by Springer Nature in Journal of Cardiovascular Translational Research
- Vol. 9 (2) , 165-166
Limitations in Translating Animal Studies to Humans in Cardiovascular Disease
- 15 January 2016
- Published by Springer Nature in Journal of Cardiovascular Translational Research
- Vol. 9 (2) , 165-166
Limitations in Translating Animal Studies to Humans in Cardiovascular Disease
- 24 August 2011
- Published by Springer Nature
- p. 1567-1569
Proteomics in Cardiovascular Disease
- Open Access
- 1 April 2009
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 8 (4) , 799-804
Using Antibody Arrays to Detect Microparticles from Acute Coronary Syndrome Patients Based on Cluster of Differentiation (CD) Antigen Expression
- 1 April 2009
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 8 (4) , 799-804
Open AccessUsing Antibody Arrays to Detect Microparticles from Acute Coronary Syndrome Patients Based on Cluster of Differentiation (CD) Antigen Expression
- 1 January 2005
- Published by Springer Nature
- p. 1567-1569
Proteomics in Cardiovascular Disease
- Open Access
- 4 November 2004
- Published by Wiley in Proteomics
- Vol. 4 (11) , 3660
Increases in leukocyte cluster of differentiation antigen expression during cardiopulmonary bypass in patients undergoing heart transplantation (vol. 4, Issue 7, pp. 1918‐1926)
See original http://dx.doi.org/10.1002/pmic.200300756
- 4 November 2004
- Published by Wiley in Proteomics
- Vol. 4 (11) , 3660
Open AccessIncreases in leukocyte cluster of differentiation antigen expression during cardiopulmonary bypass in patients undergoing heart transplantation (vol. 4, Issue 7, pp. 1918‐1926)
See original http://dx.doi.org/10.1002/pmic.200300756
- 22 June 2004
- Published by Wiley in Proteomics
- Vol. 4 (7) , 1918-1926
Increases in leukocyte cluster of differentiation antigen expression during cardiopulmonary bypass in patients undergoing heart transplantation
Cardiopulmonary bypass (CPB) is essential in heart transplantation surgery. It is also used in coronary artery grafting surgery where it has been associated with a postoperative inflammatory response. This manifests as an increase in pro‐inflammatory proteins like interleukin‐8 and tumour necrosis factor α accompanied by increases in neutrophil populations and increased expression of cluster of differentiation (CD) antigens. The latter have been investigated using flow cytometry, which is limited to the measurement of three to four CD antigens simultaneously. We have developed a novel antibody array that can simultaneously measure the expression of 72 different CD antigens. The purpose of this study was to use this technology to measure CD antigen expression in patients undergoing CPB during heart transplantation. Twelve patients undergoing this operation were studied. A preoperative sample acted as an internal control while a second sample taken during CPB was the comparator. No previous studies have examined changes in CD antigen expression during heart transplantation. We report an increase in the expression of 10 different CD antigens across all patients between the two time points.
- 22 June 2004
- Published by Wiley in Proteomics
- Vol. 4 (7) , 1918-1926
Increases in leukocyte cluster of differentiation antigen expression during cardiopulmonary bypass in patients undergoing heart transplantation
Cardiopulmonary bypass (CPB) is essential in heart transplantation surgery. It is also used in coronary artery grafting surgery where it has been associated with a postoperative inflammatory response. This manifests as an increase in pro‐inflammatory proteins like interleukin‐8 and tumour necrosis factor α accompanied by increases in neutrophil populations and increased expression of cluster of differentiation (CD) antigens. The latter have been investigated using flow cytometry, which is limited to the measurement of three to four CD antigens simultaneously. We have developed a novel antibody array that can simultaneously measure the expression of 72 different CD antigens. The purpose of this study was to use this technology to measure CD antigen expression in patients undergoing CPB during heart transplantation. Twelve patients undergoing this operation were studied. A preoperative sample acted as an internal control while a second sample taken during CPB was the comparator. No previous studies have examined changes in CD antigen expression during heart transplantation. We report an increase in the expression of 10 different CD antigens across all patients between the two time points.